Farah Seedat, Simon Procter, Ziyaad Dangor, Shannon Leahy, Sridhar Santhanam, Hima B John, Quique Bassat, Celine Aerts, Amina Abubakar, Carophine Nasambu, Romina Libster, Clara Sánchez Yanotti, Proma Paul, Jaya Chanda, Bronner P Gonçalves, Erzsébet Horváth-Puhó, Joy E Lawn, Mark Jit
INTRODUCTION: There are no published data on the long-term impact of invasive group B Streptococcus disease (iGBS) on economic costs or health-related quality of life (HRQoL) in low-income and middle-income countries. We assessed the impact of iGBS on healthcare utilisation, costs and HRQoL in Argentina, India, Kenya, Mozambique and South Africa. METHODS: Inpatient and outpatient visits, out-of-pocket (OOP) healthcare payments in the 12 months before study enrolment, and health-state utility of children and caregivers (using the EuroQol 5-Dimensions-3-Level) were collected from iGBS survivors and an unexposed cohort matched on site, age at recruitment and sex...
May 14, 2024: BMJ Global Health